The GenNext Executive Team
Scot R Weinberger
President and CEO
Scot has over thirty years of industrial experience in pioneering and commercializing cutting-edge tools for life science research. Scot is a prolific inventor and holds 22 United States Patents for solutions in liquid chromatography, ultraviolet – visible spectrometry, capillary electrophoresis, time-of-flight mass spectrometry, matrix-assisted laser desorption/ionization, protein biochip technology, tandem mass spectrometry, and surface-tethered and free-solution label-free biosensors. He has authored over thirty scientific publications, 6 book chapters, and has over 2,000 citations in the areas of translational medicine, life science research, and technology development. As an entrepreneur, Scot has been in the founding teams of Linear Instruments, Linear Scientific, Biomolecular Separations, and Ciphergen Biosystems. More recently, he founded and launched Molecular Sensing and GenNext Technologies.
Dr. Joshua Sharp
Chief Technology Officer
Dr. Sharp is a world-renowned and internationally recognized expert in HRPF. He has over twenty-one peer-reviewed articles and has presented numerous invited lectures on the subject of biopharmaceutical HRPF. Josh is also an Associate Professor of Pharmacology and Research Professor of the Research Institute of Pharmaceutical Sciences at the University of Mississippi.
Dr. Lisa Jones
Chief Science Officer
In the Department of Chemistry and Biochemistry at UCSD, the Jones Lab is a structural proteomics group that uses biochemical, analytical, and biophysical approaches to study protein interactions important in biological processes. Their research focuses on protein footprinting methods coupled with mass spectrometry to identify these interactions. A major focus of their lab is extending FPOP as an in-cell method for monitoring proteins in their native cellular environment. This method would be especially useful for membrane proteins, the largest class of drug targets, which are challenging to study in vitro owing to the difficulty of purifying these proteins. The Jones lab has further expanded FPOP for in vivo analysis in C. elegans, an animal model for human disease.
Dr. Jones received her PhD at Georgia State University studying the affinity effectors of calcium-binding proteins. She was a postdoctoral associate in the lab of Dr. Peter Prevelige at the University of Alabama-Birmingham where she used hydrogen deuterium exchange mass spectrometry to study protein interactions in virus capsids. Dr. Jones was a postdoctoral associate in the lab of Dr. Michael Gross at Washington University in St. Louis where she expanded the use of the FPOP method for studying biologics.
Robert Egan
Director of Software Engineering and Development
Bob has over 30 years’ experience of life science software development creating software solutions for: HPLC, HPCE, LCMS, MALDI-TOF, SELDI-TOF MS, FTICR, label-free biosensor (waveguide and interferometry), clinical diagnostics, and HOS analysis.
Richard Morris, PhD
Director of Sales
Dr. Richard Morris is the Director of Sales at GenNext Technologies where he brings to the table vast experience in biomedical instrumentation and biotechnology. Richard received his BS and PhD in biochemistry from Cornell and UC Riverside, respectively. His first position at Dionex was as VP of International Operations where he established global operations for the company. Next, Richard was VP of Sales & Service for Molecular Dynamics and then he was appointed President of Sigma-Aldrich Research. During his four years running this $800 million revenue division, he directed worldwide sales including managing the salesforce, marketing, and associated services. Richard integrated multiple brands into the Research Division, developed the e-commerce website, created a national account strategy, instituted product management, and opened new markets for the company. Subsequently, he became President at CambridgeSoft Corp., a company specializing in software solutions for chemical compound modeling and e-notebooks. More recently, Richard was the CEO of PharmaSeq, a private New Jersey-based developer of electronic tags that are used in authentication and synthetic biology. PharmaSeq was recently sold to a private group of investors. He has also consulted for several small and large biotechnology corporations throughout his extensive career.
Bridget Fenker
Director of Marketing
Bridget is GenNext’s Director of Marketing where she is responsible for establishing the company brand, designing and implementing the marketing strategy, and generating market awareness. Before GenNext, Bridget held senior-level marketing positions with Synthego and 10X Genomics where she launched gene editing and single-cell analysis technologies respectively. Prior to that, Bridget was the Principal of Marketing on Demand for Life Sciences (MOD.LS) — an agency focused on launching innovative products and establishing world-class brands for emerging companies. A partial list of clients included Thermo Fisher, BD Biosciences, Parabase Genomics, QuantaLife, Scipio biosciences, CellPly, and others. Prior to MOD.LS, Bridget held senior marketing, communications, field marketing, and international communications positions with Eksigent Technologies, Agilent Technologies, Ciphergen Biosystems, and Applied Biosystems.
Emily Chea, PhD
Applied Research Manager
Dr. Chea is the Applied Research Manager at GenNext Technologies. She received her PhD while studying with Professor Lisa Jones at the University of Maryland, Baltimore. Emily is a highly skilled research scientist in the use of LC-MS techniques for proteomics studies, focusing on utilizing IC-FPOP for proteome-wide structural biology to characterizing cellular drug–target interactions. Emily has made significant contributions to the development of FPOP and HRPF with particular emphasis towards in-cell FPOP (IC-FPOP).
Raina Schally
Operations Manager